Moderna and Merck report positive results for mRNA cancer vaccine
Axios · August 19, 2026Original source ↗
What happened
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, successfully prevented the recurrence or spread of skin cancer in a late-stage clinical trial. The therapy was tested in combination with Merck's Keytruda in over 1,100 patients with high-risk melanoma.
Why it matters
The results could pave the way for advancements in personalized cancer treatments and impact future cancer therapies.
How this story affects people
How does this story affect you if you are a patient with high-risk melanoma?
The success of this mRNA cancer vaccine could offer you a new treatment option that may significantly reduce the risk of your cancer returning or spreading. This advancement in personalized medicine could lead to more effective therapies tailored specifically for your condition.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your Ripple